** Shares of Avadel Pharmaceuticals AVDL.O fall ~25% to $8.01 premarket
** Late on Wednesday AVDL forecast 2025 rev in the range of $240 mln to $260 mln
** Analysts on average estimate total revenue of about $267.6 mln -LSEG data
** At least two brokerages cut PT on AVDL following the disappointing 2025 outlook
** H.C.Wainwright analysts expect a slower revenue ramp up for its sleep disorder drug Lumryz
** Up to last close, stock down ~32% over the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。